von Moltke Lisa 4
4 · Zenas BioPharma, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma (ZBIO) CMO Lisa von Moltke Receives Award
What Happened
Lisa von Moltke, Head of Research & Development and Chief Medical Officer of Zenas BioPharma (ZBIO), was granted a derivative award covering 150,000 shares on June 15, 2026. The grant is reported as an acquisition (Code A) with a reported price of $0.00 per share (derivative).
Key Details
- Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (filed timely).
- Amount: 150,000 derivative securities granted; reported price $0.00.
- Vesting: 25% vests on June 15, 2027 (one-year cliff), remainder vests in equal monthly installments over the following 36 months, subject to continued service (per footnote).
- Shares owned after transaction: not specified in the filing.
- Notes: Footnote explicitly describes this as an option-style vesting schedule; filing shows an award/grant rather than a purchase or sale.
Context
This was a grants/award transaction (not a market purchase or sale). For retail investors, grants indicate compensation and potential future dilution as options vest and are exercised; they do not by themselves signal immediate buying or selling of stock.
Insider Transaction Report
Form 4
von Moltke Lisa
See Remarks
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-15+150,000→ 150,000 totalExercise: $18.71Exp: 2036-06-15→ Common Stock (150,000 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Signature
By: /s/ Jeffrey Held, Attorney-in-Fact|2026-06-17